|
10 Jun 2020 |
Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis
|
|
10 Jun 2020 |
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
|
|
09 Jun 2020 |
Versant Ventures Launches Lycia Therapeutics with $50 Million
|
|
09 Jun 2020 |
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
|
|
09 Jun 2020 |
A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19
|
|
08 Jun 2020 |
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
|
|
08 Jun 2020 |
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
|
|
08 Jun 2020 |
Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020
|
|
08 Jun 2020 |
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
|
|
08 Jun 2020 |
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
|
|
07 Jun 2020 |
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
|
|
05 Jun 2020 |
FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
|
|
05 Jun 2020 |
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
|
|
05 Jun 2020 |
Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure
|
|
03 Jun 2020 |
Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease
|
|
03 Jun 2020 |
Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer
|
|
03 Jun 2020 |
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
|
|
03 Jun 2020 |
Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis
|
|
03 Jun 2020 |
Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis
|
|
03 Jun 2020 |
Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated
|
|
03 Jun 2020 |
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor, CFI-402411
|
|
02 Jun 2020 |
Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma
|
|
01 Jun 2020 |
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
|
|
01 Jun 2020 |
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
|
|
01 Jun 2020 |
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
|
